To facilitate the retention of IL2v in the tumor microenvironment, IL2v was fused to an antifibroblast activation protein-α (FAP) antibody (FAP-IL2v), and the resulting immunocytokine was named simlukafusp alfa (formerly RO6874281/RG7461; ref. 7). This evidence concerns the gene FAP and neoplasm.